To examine the Breast-GPA tool and its variables alongside selected therapies to understand factors influencing survival outcomes in patients with brain metastases from breast cancer, specifically focusing on treatment modalities and their impact on overall survival.
Key Findings:
Median age of patients was 54 years; majority were female, white, and non-Hispanic.
Invasive ductal carcinoma was the most common histological type (81.7%).
86.5% of patients received chemotherapy, with a significant portion receiving neo-adjuvant treatment.
Median overall survival from brain metastasis diagnosis was significantly influenced by treatment modalities, highlighting the importance of tailored therapies.
Interpretation:
The study highlights the importance of multimodal treatment approaches and the Breast-GPA tool in predicting survival outcomes for breast cancer patients with brain metastases.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the generalizability of the findings.
Lack of data on clinical trial participation during treatment limits understanding of treatment efficacy.
Potential confounding factors not accounted for in the analysis may skew results.
Conclusion:
The findings underscore the need for tailored treatment strategies based on individual patient characteristics and the potential utility of the Breast-GPA in clinical decision-making, emphasizing the importance of personalized approaches in managing breast cancer patients with brain metastases.
by Ahmad Alhalabi, Theresa Abdo, Ali Hijazi, Mohamed Mohanna, Rami Tfayli, María Herrán, Saad Sabbagh, Saffet Guleryuz, Razan Mohanna, Rashid Mahrous, Kaylee Sarna, Surabhi Ranjan, Christopher W Fleming, Zeina Nahleh
